OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial.

Background The phase III prime-boost trial of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E spanned 2003 to 2009 in Thailand. Both candidates express HIV CRF 01_AE and subtype B antigens, the predominant circulating HIV-1 subtypes in Thailand. This preliminary study assessed cellmediated immune (CMI) responses, viral load and CD4 counts in a subset (N=47) of anti-retroviral naive incident infections (< 270 days after estimated infection) that occurred during the trial.